We are live on ! Find out more
FRTX

Fresh Tracks Therapeutics, Inc. Common Stock

Delisted

FRTX was delisted on the 18th of December, 2023.

23 hedge funds and large institutions have $6.87M invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 6

5% less capital invested

Capital invested by funds: $7.2M → $6.87M (-$333K)

18% less funds holding

Funds holding: 2823 (-5)

80% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 5

Holders
23
Holders Change
-5
Holders Change %
-17.86%
% of All Funds
0.57%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
1
Increased
7
Reduced
6
Closed
5
Calls
$116K
Puts
Net Calls
+$116K
Net Calls Change
-$115K
Name Holding Trade Value Shares
Change
Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
-$12K -14 Closed
MLFP
27
MPS Loria Financial Planners
Illinois
-$7K -10 Closed

FRTX Hedge Fund Activity: Q3 2017 in Review

23 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q3 2017, worth a combined $6.87M — down 4.6% from $7.2M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of FRTX and 1 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 7 added.

The largest buyer was Ariel Investments, adding an estimated $493K. The largest seller was Fidelity Investments, cutting an estimated $520K.

  • 23 institutional investors held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q3 2017, down from 28 in Q2 2017.
  • Funds reported $6.87M of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q3 2017, down 4.6% quarter-over-quarter.
  • 1 fund opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q3 2017 and 5 closed out, a net change of -4 holders.
  • The largest Fresh Tracks Therapeutics, Inc. Common Stock buyer in Q3 2017 was Ariel Investments, an estimated $493K added.
  • The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q3 2017 was Fidelity Investments, an estimated $520K sold.

Based on aggregated 13F filings for Q3 2017.